Eli Lilly and Company (LLY) Financial Statements
Eli Lilly and Company (LLY) reported trailing twelve-month revenue of $79.7B (up 49.6% year on year) and net income of $26.7B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $18.2B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LLYEli Lilly and CompanyFollow LLY — free
—
Price chart with a free account
- Market cap
- 1.20T
- P/E TTM
- 42.7
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.84 | 23.08 | 24.29 | 22.60 | 23.11 | 19.62 | 19.96 | 21.22 | 19.97 | 21.49 | 22.32 | 24.54 | 28.32 | 28.54 | 34.12 | 45.04 | 65.18 | 79.67 | |
| Gross profit | 17.59 | 18.71 | 19.22 | 17.81 | 18.21 | 14.68 | 14.92 | 15.57 | 13.90 | 16.81 | 17.60 | 19.06 | 21.01 | 21.91 | 27.04 | 36.63 | 54.13 | 66.44 | |
| Research & development | 4.33 | 4.88 | 5.02 | 5.28 | 5.53 | 4.73 | 4.80 | 5.31 | 5.10 | 5.05 | 5.60 | 5.98 | 6.93 | 7.19 | 9.31 | 10.99 | 13.34 | 14.60 | |
| Pre-tax income | 5.36 | 6.53 | 5.35 | 4.90 | 5.89 | 3.00 | 2.79 | 3.37 | 2.30 | 3.68 | 5.27 | 7.23 | 6.16 | 6.81 | 6.55 | 12.68 | 25.73 | 33.60 | |
| Income tax | 1.03 | 1.46 | 1.00 | 1.32 | 1.20 | 0.61 | 0.38 | 0.64 | 2.39 | 0.53 | 0.63 | 1.04 | 0.57 | 0.56 | 1.31 | 2.09 | 5.09 | 6.88 | |
| Net income | 4.33 | 5.07 | 4.35 | 4.09 | 4.68 | 2.39 | 2.41 | 2.74 | -0.20 | 3.23 | 8.32 | 6.19 | 5.58 | 6.24 | 5.24 | 10.59 | 20.64 | 26.71 | |
| Diluted EPS ($) | — | 4.58 | 3.90 | 3.66 | 4.32 | 2.23 | 2.26 | 2.58 | -0.19 | 3.13 | 8.89 | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 | 29.80 | |
| Diluted shares (bn) | — | 1.106 | 1.114 | 1.117 | 1.085 | 1.074 | 1.066 | 1.062 | 1.052 | 1.034 | 0.936 | 0.913 | 0.912 | 0.905 | 0.903 | 0.904 | 0.899 | — |
USD billions · SEC XBRL
Eli Lilly and Company — questions
- What is Eli Lilly and Company's revenue?
- $79.7B over the twelve months to 2026-06-30, up 49.6% year on year, from its 10-Q and 10-K filings.
- What is Eli Lilly and Company's net income?
- $26.7B over the twelve months to 2026-06-30.
- What is Eli Lilly and Company's free cash flow?
- $18.2B over the twelve months to 2026-06-30.
- What are Eli Lilly and Company's diluted earnings per share?
- $29.80 over the twelve months to 2026-06-30.
Every figure on this page comes from Eli Lilly and Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.